Participants’ comorbidities and smoking status
| COVID-19 hospitalised (n=24) | COVID-19 self-isolated (n=31) | Controls (n=44) | P value (significant for <0.05) | |
| Chronic rhinosinusitis | 1 (6.7%) | 0 | 1 (2.3%) | 0.427 |
| Allergies | 0 | 3 (10.0%) | 11 (25.6%) | 0.042 |
| Lung disease | 2 (6.7%) | 2 (13.3%) | 3 (7.0%) | 0.755 |
| Hypertension | 6 (40.0%) | 5 (16.7%) | 10 (23.3%) | 0.252 |
| Diabetes | 1 (6.7%) | 0 | 4 (9.3%) | 0.193 |
| Obesity | 4 (26.7%) | 0 | 3 (7.0%) | 0.011 |
| Head injury | 0 | 0 | 3 (7.0%) | 0.283 |
| Heart disease | 2 (13.3%) | 0 | 2 (4.7%) | 0.113 |
| Cancer, no CTX/RTX | 0 | 1 (3.3%) | 1 (2.3%) | 1.000 |
| Cancer, treated with CTX/RTX | 1 (6.7%) | 0 | 0 | 0.170 |
| Smoking | 1 (6.7%) | 3 (10.7%) | 4 (11.4%) | 1.000 |
Results are presented as number of cases and percentage . Values of p were obtained by Fisher’s exact test.
CTX, chemotherapy; RTX, radiotherapy.